Literature DB >> 25412872

Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria.

Wallace J Brownlee1, Josephine K Swanton1, Daniel R Altmann2, Olga Ciccarelli3, David H Miller3.   

Abstract

Entities:  

Keywords:  MRI; MULTIPLE SCLEROSIS

Mesh:

Year:  2014        PMID: 25412872      PMCID: PMC4451169          DOI: 10.1136/jnnp-2014-308675

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
The McDonald criteria allow multiple sclerosis (MS) to be diagnosed in patients with a clinically isolated syndrome (CIS) who have MRI evidence of dissemination in time and space.1–3 There have been successive versions of the criteria in 2001,1 20052 and 20103 with different requirements for dissemination in time and space. Although each version has been shown to have a high sensitivity and specificity for the development of clinically-definite MS (CDMS), few studies have investigated how much sooner4 and how more often5 MS can be diagnosed in patients with CIS using the McDonald criteria. We recruited 178 patients with CIS presenting to Moorfields Eye Hospital and the National Hospital for Neurology and Neurosurgery between 1995 and 2004. The study was approved by ethics committees at both hospitals. Patients were seen at baseline, then for follow-up after 3 months, 1 year, 3 years and 6 years. At each study visit informed consent was obtained. Patients were assessed with a detailed review of neurological symptoms and neurological examination. Relapses were recorded at study visits, but patients were also encouraged to contact the research team at the time of new neurological symptoms. MRI of the brain and whole spine was obtained at each visit on the same 1.5 T Signa scanner, as described elsewhere.6 Each scan was reviewed by a neuroradiologist blinded to the patient's clinical status. The number, location and activity (ie, gadolinium enhancement) of T2 lesions was recorded. During follow-up CDMS was defined according to Poser criteria. The McDonald criteria were applied retrospectively and MS diagnosed when MRI criteria for dissemination in time/space were met or at the time of a second clinical attack, whichever occurred first.1–3 Only patients with at least one follow-up MRI and at least 36 months of clinical follow-up were included in this analysis. Comparison of within-patient times to MS diagnosis by each diagnostic criterion used the non-parametric one-sample Wilcoxon signed-rank test, since time differences were skewed. Proportions of diagnoses by the different criteria in the same patients were compared using McNemar's test for paired proportions (exact form). Analyses were carried out in Stata 13.1 (Stata Corporation, College Station, Texas, USA). Statistical significance is reported at p<0.05. One hundred and fifty-seven patients (mean age 32.4 years, 64% female) had sufficient clinical and MRI follow-up to be included in this analysis. CIS locations were optic neuritis in 128, brainstem 18, spinal cord 10 and hemispheric 1. Mean follow-up was 5.8 years (range 3.0–11.9 years). One patient was treated with disease-modifying therapy prior to developing CDMS. Seventy-one (45%) patients were classified as CDMS, 69 after a second clinical attack and two developed secondary progressive MS following a CIS. Figure 1 shows Kaplan-Meier curves for the time to diagnosis of MS using the Poser and McDonald criteria for patients with CIS who developed CDMS. Mean time to CDMS was 23.1 months compared with 12.0, 10.5 and 6.2 months using the 2001, 2005 and 2010 McDonald criteria (p<0.0001 for comparisons with time to CDMS).
Figure 1

Kaplan-Meier survival curve showing time to diagnosis of multiple sclerosis (MS) using Poser and McDonald criteria among patients with clinically isolated syndrome who developed clinically-definite MS.

Kaplan-Meier survival curve showing time to diagnosis of multiple sclerosis (MS) using Poser and McDonald criteria among patients with clinically isolated syndrome who developed clinically-definite MS. Of 86 (55%) who did not have a second attack, 24 (28%), 26 (30%) and 36 (42%) satisfied 2001, 2005 and 2010 McDonald criteria with MRI evidence of dissemination in time and space (MRI-only MS). Significantly more patients with CIS had MRI-only MS when applying the 2010 criteria, compared with the 2001 (p=0.0002) and 2005 criteria (p=0.001). Most patients with MRI-only MS satisfied the MRI criteria in the first year after CIS; 18 (75%), 18 (69%) and 26 (75%) patients using the 2001, 2005 and 2010 criteria respectively. When all 157 patients with CIS were considered together, 71 (45%) had CDMS, 36 (23%) had MRI-only MS and 50 (32%) did not have MS using the 2010 McDonald criteria after 6 years. Establishing a diagnosis of MS at an earlier time point provides an explanation for worrying symptoms and allows for timely discussions about the nature of MS and its management, including use of disease-modifying treatments. In this large CIS cohort, MS was diagnosed significantly earlier using the McDonald criteria. The time gain with each revision of the criteria reflects the less stringent requirements for dissemination in time and space, while retaining high specificity.1–3 Among patients with CIS in this study who ultimately developed CDMS, the mean time to diagnosis of MS halved from 12 months with the 2001 criteria to 6.2 months with the 2010 criteria, a time gain of 16.9 months compared with mean time to CDMS. The time gain using the McDonald criteria was significantly greater in this study than in a previous hospital-based series.4 However, in that study spinal imaging was not performed and not all patients had postcontrast T1-weighted scans or follow-up MRI, both important for demonstrating dissemination in time. The McDonald criteria identify a significant number of patients with CIS with MRI evidence of dissemination of time and space in the absence of further clinical events,5 and the number has increased as the criteria have been revised. These patients probably have a form of MS that remains largely subclinical. Given the relatively high frequency of MRI-only MS (almost a third of those diagnosed using the 2010 criteria), the possibility arises that the new diagnostic criteria are identifying a milder form of MS than in the past when the diagnosis was based on clinical course alone. There is the potential for the natural history of relapse-onset MS to be being favourably modified by changes to the diagnostic criteria, independent of any effect of disease-modifying treatments.7 These issues are important when counselling patients with CIS about prognosis and in deciding whether to initiate treatment. One potential limitation of our study is an over-representation of patients with optic neuritis, which may have a more benign prognosis that other CIS types.8 However, almost 80% of patients with optic neuritis had baseline MRI abnormalities, indicating a group at high-risk for developing MS. In conclusion, the McDonald criteria allow MS to be diagnosed sooner and more often in patients with CIS. While the McDonald criteria facilitate an earlier diagnosis of MS, up to a third of patients with CIS who satisfy the 2010 criteria do not have further clinical events, at least in the medium-term.
  8 in total

1.  Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.

Authors:  J K Swanton; K T Fernando; C M Dalton; K A Miszkiel; D R Altmann; G T Plant; A J Thompson; D H Miller
Journal:  Mult Scler       Date:  2010-01-19       Impact factor: 6.312

2.  Is optic neuritis more benign than other first attacks in multiple sclerosis?

Authors:  Mar Tintoré; Alex Rovira; Jordi Rio; Carlos Nos; Elisensa Grivé; Neus Téllez; Raul Pelayo; Manuel Comabella; Xavier Montalban
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

3.  Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromes.

Authors:  T F Runia; N Jafari; R Q Hintzen
Journal:  Eur J Neurol       Date:  2013-07-30       Impact factor: 6.089

4.  MRI only conversion to multiple sclerosis following a clinically isolated syndrome.

Authors:  D T Chard; C M Dalton; J Swanton; L K Fisniku; K A Miszkiel; A J Thompson; G T Plant; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-02       Impact factor: 10.154

5.  Will Rogers phenomenon in multiple sclerosis.

Authors:  Maria Pia Sormani; Mar Tintorè; Marco Rovaris; Alex Rovira; Xavier Vidal; Paolo Bruzzi; Massimo Filippi; Xavier Montalban
Journal:  Ann Neurol       Date:  2008-10       Impact factor: 10.422

Review 6.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

7.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

8.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

  8 in total
  15 in total

1.  Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.

Authors:  Wallace J Brownlee; Katherine A Miszkiel; Carmen Tur; Frederik Barkhof; David H Miller; Olga Ciccarelli
Journal:  Neurology       Date:  2018-08-17       Impact factor: 9.910

2.  Should the symptomatic region be included in dissemination in space in MRI criteria for MS?

Authors:  Wallace J Brownlee; Josephine K Swanton; Katherine A Miszkiel; David H Miller; Olga Ciccarelli
Journal:  Neurology       Date:  2016-07-15       Impact factor: 9.910

Review 3.  Involvement of the Intestinal Microbiota in the Appearance of Multiple Sclerosis: Aloe vera and Citrus bergamia as Potential Candidates for Intestinal Health.

Authors:  Jessica Maiuolo; Vincenzo Musolino; Micaela Gliozzi; Cristina Carresi; Federica Scarano; Saverio Nucera; Miriam Scicchitano; Francesca Oppedisano; Francesca Bosco; Roberta Macri; Ernesto Palma; Carolina Muscoli; Vincenzo Mollace
Journal:  Nutrients       Date:  2022-06-29       Impact factor: 6.706

4.  Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome.

Authors:  Roos M van der Vuurst de Vries; Julia Y Mescheriakova; Yu Yi M Wong; Tessel F Runia; Naghmeh Jafari; Johnny P Samijn; Janet W K de Beukelaar; Beatrijs H A Wokke; Theodora A M Siepman; Rogier Q Hintzen
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

Review 5.  Multiple sclerosis, a treatable disease .

Authors:  Anisha Doshi; Jeremy Chataway
Journal:  Clin Med (Lond)       Date:  2017-12       Impact factor: 2.659

Review 6.  The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.

Authors:  Pascal Sati; Jiwon Oh; R Todd Constable; Nikos Evangelou; Charles R G Guttmann; Roland G Henry; Eric C Klawiter; Caterina Mainero; Luca Massacesi; Henry McFarland; Flavia Nelson; Daniel Ontaneda; Alexander Rauscher; William D Rooney; Amal P R Samaraweera; Russell T Shinohara; Raymond A Sobel; Andrew J Solomon; Constantina A Treaba; Jens Wuerfel; Robert Zivadinov; Nancy L Sicotte; Daniel Pelletier; Daniel S Reich
Journal:  Nat Rev Neurol       Date:  2016-11-11       Impact factor: 42.937

7.  An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis.

Authors:  J William L Brown; Matteo Pardini; Wallace J Brownlee; Kryshani Fernando; Rebecca S Samson; Ferran Prados Carrasco; Sebastien Ourselin; Claudia A M Gandini Wheeler-Kingshott; David H Miller; Declan T Chard
Journal:  Brain       Date:  2017-01-02       Impact factor: 13.501

Review 8.  Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.

Authors:  X Armoiry; A Kan; G J Melendez-Torres; R Court; P Sutcliffe; P Auguste; J Madan; C Counsell; A Clarke
Journal:  J Neurol       Date:  2018-01-22       Impact factor: 4.849

9.  Systematic review of prediction models in relapsing remitting multiple sclerosis.

Authors:  Fraser S Brown; Stella A Glasmacher; Patrick K A Kearns; Niall MacDougall; David Hunt; Peter Connick; Siddharthan Chandran
Journal:  PLoS One       Date:  2020-05-26       Impact factor: 3.240

10.  MRI in predicting conversion to multiple sclerosis within 1 year.

Authors:  Ayelet Eran; Melissa García; Robair Malouf; Noam Bosak; Raz Wagner; Ester Ganelin-Cohen; Elinor Artsy; Alla Shifrin; Ayal Rozenberg
Journal:  Brain Behav       Date:  2018-08-02       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.